Last quarter (Q2 2023), Allarity Therapeutics, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Allarity Therapeutics, Inc.'s net income was $-5.55M. See Allarity Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ -874.00K	-	$ 50.00M	$ 0.00	$ 120.00K
Cost of Revenue	-	-	-	-	-
Gross Profit	$ -874.00K	-	$ 50.00M	-	-
Operating Expense	$ -1.83M	$ 16.89M	$ 26.56M	$ 8.32M	$ 10.24M
Operating Income	$ -8.36M	$ -16.89M	$ -26.56M	$ -8.32M	$ -10.12M
Net Non Operating Interest Income Expense	$ 2.38M	$ 787.00K	$ -1.35M	$ -320.00K	$ -3.31M
Other Income Expense	$ 387.94K	$ 561.00K	$ -1.48M	$ 2.22M	$ -5.55M
Pretax Income	$ -5.59M	$ -17.58M	$ -26.52M	$ -6.42M	$ -18.98M
Tax Provision	$ -303.00K	$ -1.52M	$ 133.00K	$ 198.00K	$ -4.58M
Earnings From Equity Interest Net Of Tax	$ 17.13M	-	-	-	-
Net Income Common Stockholders	$ -4.16M	$ -21.05M	$ -26.65M	$ -6.60M	$ -14.31M
Basic EPS	$ -33.20	$ -2.21	$ -167.60	$ -1.12	$ -1.77
Diluted EPS	$ -34.27	$ -2.21	$ -167.60	$ -1.12	$ -1.77
Basic Average Shares	$ 13.13M	$ 9.53M	$ 158.97K	$ 4.53M	$ 8.08M
Diluted Average Shares	$ 13.13M	$ 9.53M	$ 158.97K	$ 4.53M	$ 8.08M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ -1.83M	$ 16.89M	$ 26.56M	$ 8.32M	$ 10.24M
Net Income From Continuing And Discontinued Operation	$ -2.34M	$ -16.06M	$ -26.65M	$ -6.60M	$ -14.31M
Normalized Income	$ -9.29M	-	-	$ -8.64M	$ -10.09M
Interest Expense	-	-	-	$ 320.00K	$ 3.31M
EBIT	$ -6.00M	$ -17.77M	$ -25.17M	$ -6.10M	$ -15.66M
EBITDA	$ -6.39M	$ -17.71M	$ -23.71M	$ -6.05M	$ -15.61M

Currency in USD

Allarity Therapeutics, Inc. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing